BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37914241)

  • 1. [Guillain-Barré syndrome associated with Epstein-Barr virus and cytomegalovirus reactivation during treatment for chronic graft-versus-host disease after allogeneic bone marrow transplantation].
    Hosoi H; Tane M; Kosako H; Sakaki A; Wada Y; Nakayama Y; Hiroi T; Hori Y; Yamashita Y; Mushino T; Murata S; Nishikawa A; Miyamoto K; Ito H; Sonoki T
    Rinsho Ketsueki; 2023; 64(10):1280-1285. PubMed ID: 37914241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
    Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
    Front Immunol; 2020; 11():620891. PubMed ID: 33664733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
    Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
    Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
    Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
    Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation.
    Li SS; Zhang N; Jia M; Su M
    Front Cell Infect Microbiol; 2022; 12():818167. PubMed ID: 35402291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
    Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
    Hu J; Zhao J; Wang C; Jia M; Su M; Li S
    Ann Hematol; 2023 Dec; 102(12):3593-3601. PubMed ID: 37831153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
    Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
    Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
    Lebon D; Dujardin A; Caulier A; Joris M; Charbonnier A; Gruson B; Quint M; Castelain S; François C; Lacassagne MN; Guillaume N; Marolleau JP; Morel P
    Leuk Res; 2023 Feb; 125():107005. PubMed ID: 36580876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
    Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
    Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
    Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
    de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation.
    Gao F; Shi Z; Shi J; Luo Y; Yu J; Fu H; Lai X; Liu L; Yuan Z; Zheng Z; Huang H; Zhao Y
    HLA; 2024 Jan; 103(1):e15320. PubMed ID: 38081622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome post renal transplant: A systematic review.
    Ostman C; Chacko B
    Transpl Infect Dis; 2019 Feb; 21(1):e13021. PubMed ID: 30403433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
    Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
    PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
    Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
    Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.